Molecular and Phenotypic Characterisation of Paediatric Glioma Cell Lines as Models for Preclinical Drug Development
暂无分享,去创建一个
Paul Workman | Darren Hargrave | Chris Jones | Dorine A. Bax | Anita Grigoriadis | Marta Viana-Pereira | Lara Perryman | Denise Sheer | Nathalie Gaspar | Gilles Vassal | A. Grigoriadis | R. Reis | R. Williams | D. Bax | G. Vassal | Chris Jones | P. Workman | D. Sheer | D. Hargrave | S. Little | T. Jones | L. Perryman | Suzanne E. Little | Lynley Marshall | Tania A. Jones | Richard D. Williams | Rui M. Reis | Andrew D. J. Pearson | A. Pearson | L. Marshall | N. Gaspar | M. Viana-Pereira | Chris Jones
[1] R. Mirimanoff,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[2] P. Burger,et al. Frequent Gains at Chromosome 7q34 Involving BRAF in Pilocytic Astrocytoma , 2008, Journal of neuropathology and experimental neurology.
[3] J. Schouten,et al. Methylation-Specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences , 2005, Nucleic acids research.
[4] Jason E. Stewart,et al. Minimum information about a microarray experiment (MIAME)—toward standards for microarray data , 2001, Nature Genetics.
[5] W. Poon,et al. Genetic alterations in pediatric high-grade astrocytomas. , 1999, Human pathology.
[6] Erwin G. Van Meir,et al. Aberrant methylation and down-regulation of TMS1/ASC in human glioblastoma. , 2004, The American journal of pathology.
[7] D. Busam,et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.
[8] R. Mirimanoff,et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.
[9] P. Wesseling,et al. MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas , 2007, Laboratory Investigation.
[10] K. Wong,et al. Genome-wide allelic imbalance analysis of pediatric gliomas by single nucleotide polymorphic allele array. , 2006, Cancer research.
[11] A Leviton,et al. Limitations of the World Health Organization classification of childhood supratentorial astrocytic tumors , 2000, Cancer.
[12] P. Liberski,et al. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] R. Ellenbogen,et al. O6-Methylguanine-DNA Methyltransferase, O6-Benzylguanine, and Resistance to Clinical Alkylators in Pediatric Primary Brain Tumor Cell Lines , 2005, Clinical Cancer Research.
[14] S. Horvath,et al. Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma , 2008, PLoS medicine.
[15] Emily C. Brantley,et al. Signal Transducer and Activator of Transcription-3: A Molecular Hub for Signaling Pathways in Gliomas , 2008, Molecular Cancer Research.
[16] D. Gisselsson,et al. Glial Progenitor-Like Phenotype in Low-Grade Glioma and Enhanced CD133-Expression and Neuronal Lineage Differentiation Potential in High-Grade Glioma , 2008, PloS one.
[17] Howard A. Fine,et al. Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08 , 2006, Clinical Cancer Research.
[18] A. Ashworth,et al. Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization , 2006, Laboratory Investigation.
[19] S. Zacharoulis,et al. Pediatric CNS tumors: current treatment and future directions , 2007, Expert review of neurotherapeutics.
[20] M. Massimino,et al. Phase II trial of temozolomide in children with recurrent high-grade glioma , 2006, Journal of Neuro-Oncology.
[21] M. Weller,et al. Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma. , 2006, Current pharmaceutical design.
[22] Mitsutoshi Nakamura,et al. Molecular pathogenesis of pediatric astrocytic tumors. , 2007, Neuro-oncology.
[23] H. Donninger,et al. The RASSF1A tumor suppressor , 2007, Journal of Cell Science.
[24] K. Geiger,et al. Cytogenetic and molecular cytogenetic analyses in diffuse astrocytomas. , 2004, Cancer genetics and cytogenetics.
[25] H. Friedman,et al. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors , 2007, Cancer.
[26] T. Zhou,et al. O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[28] G. Barger,et al. In vitro Drug Response and Molecular Markers Associated with Drug Resistance in Malignant Gliomas , 2006, Clinical Cancer Research.
[29] T. Merchant,et al. Temozolomide after Radiotherapy for Newly Diagnosed High-grade Glioma and Unfavorable Low-grade Glioma in Children , 2006, Journal of Neuro-Oncology.
[30] H. Wheeler,et al. Contribution of DNA repair mechanisms to determining chemotherapy response in high-grade glioma , 2008, Journal of Clinical Neuroscience.
[31] R. Eils,et al. An optimized, fully automated system for fast and accurate identification of chromosomal rearrangements by multiplex-FISH (M-FISH) , 1998, Cytogenetic and Genome Research.
[32] N. Potter,et al. Genomic deletions correlate with underexpression of novel candidate genes at six loci in pediatric pilocytic astrocytoma. , 2008, Neoplasia.
[33] D. Ellison,et al. Clinical and molecular characteristics of malignant transformation of low-grade glioma in children. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] R. Bjerkvig,et al. DNA repair and cancer stem-like cells--potential partners in glioma drug resistance? , 2008, Cancer treatment reviews.
[35] Karin Reed,et al. Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. , 2002, Biochemical pharmacology.
[36] Allan H Friedman,et al. Phase II trial of gefitinib in recurrent glioblastoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] P. Allebeck,et al. Short communication , 1994, Agroforestry Systems.
[38] H. Jürgens,et al. Pediatric high-grade astrocytomas show chromosomal imbalances distinct from adult cases. , 2001, The American journal of pathology.
[39] A. Reddy. Advances in biology and treatment of childhood brain tumors , 2001, Current neurology and neuroscience reports.
[40] A. Look,et al. Oncogene amplification in pediatric brain tumors. , 1990, Cancer research.
[41] G. Vassal,et al. Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. , 2009, Cancer research.